Company newsCompany release

Johnson & Johnson JNJ

Johnson & Johnson agrees to acquire Ollin Biosciences

Johnson & Johnson said the upfront payment is $2.2 billion, with potential additional regulatory and commercial milestone payments.

GetSignal 

Share
Download on the App StoreGet it on Google Play

Free on iOS and Android

Johnson & Johnson said on November 16, 2026 that it has entered into a definitive agreement to acquire Ollin Biosciences, Inc., a clinical-stage biopharmaceutical company developing therapies for serious eye diseases.

Key facts

Upfront payment
$2.2 billion
Target
Ollin Biosciences, Inc.
Target stage
Clinical-stage
Additional payments
Potential regulatory and commercial milestone payments

All JNJ news

Source: The company's release on Business Wire, November 16, 2026.

Written by GetSignal with AI from the company's press release. How we make news

Not investment advice.

More company news

Johnson & Johnson first, then the newest

All company news